ResMed (RMD) Scheduled to Post Quarterly Earnings on Thursday

ResMed (NYSE:RMD) will issue its quarterly earnings data after the market closes on Thursday, October 24th. Analysts expect the company to announce earnings of $2.03 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, beating the consensus estimate of $2.03 by $0.05. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same quarter last year, the firm earned $1.60 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Price Performance

NYSE:RMD opened at $238.46 on Thursday. The stock has a 50 day moving average price of $237.80 and a 200 day moving average price of $215.36. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59. The stock has a market cap of $35.03 billion, a PE ratio of 36.63, a P/E/G ratio of 2.14 and a beta of 0.69. ResMed has a one year low of $132.24 and a one year high of $255.18.

ResMed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were paid a dividend of $0.53 per share. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $2.12 annualized dividend and a yield of 0.89%. ResMed’s dividend payout ratio (DPR) is 32.57%.

Insiders Place Their Bets

In other ResMed news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $212.16, for a total transaction of $212,160.00. Following the completion of the sale, the chief financial officer now directly owns 89,056 shares of the company’s stock, valued at $18,894,120.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other ResMed news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $212.16, for a total transaction of $212,160.00. Following the completion of the sale, the chief financial officer now directly owns 89,056 shares of the company’s stock, valued at $18,894,120.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kaushik Ghoshal sold 4,260 shares of ResMed stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $238.48, for a total value of $1,015,924.80. Following the sale, the insider now directly owns 21,788 shares of the company’s stock, valued at $5,196,002.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,874 shares of company stock valued at $28,151,142 in the last ninety days. Insiders own 1.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RMD. Royal Bank of Canada raised their target price on ResMed from $206.00 to $224.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 1st. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Tuesday, October 1st. Bank of America raised their target price on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Oppenheimer cut ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Finally, Baird R W raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $218.18.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.